Irbesartan Stada

Irbesartan, the active ingredient in Irbesartan Stada, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is prescribed to lower elevated blood pressure and to protect kidney function in patients with diabetic nephropathy.

GNH USA supplies Irbesartan Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for each batch. Clients benefit from reliable supply chains and responsive technical support throughout the ordering process.

Irbesartan is an angiotensin II receptor blocker used to manage conditions related to the renin‑angiotensin system.

- Hypertension: lowers blood pressure to reduce cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage in type 2 diabetes. - Left ventricular hypertrophy: helps reduce blood‑pressure‑related cardiac strain.

Common side effects are generally mild and may resolve with continued therapy.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or weak. - Nausea: upset stomach or urge to vomit. - Diarrhea: loose, watery stools. - Upper respiratory infection: mild cold‑like symptoms.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat that may impair breathing. - Severe hyperkalemia: markedly elevated potassium levels that can affect heart rhythm. - Acute kidney injury: sudden decline in renal function. - Hepatic injury: signs of liver dysfunction such as jaundice. - Myocardial infarction: rare occurrence of heart attack.

Before initiating therapy, clinicians should assess patient‑specific factors and monitor relevant parameters.

- Blood pressure monitoring: ensure adequate control and avoid hypotension. - Renal function assessment: check serum creatinine and eGFR regularly. - Serum potassium measurement: monitor for hyperkalemia, especially with concomitant potassium‑sparing agents. - Hepatic impairment caution: use with care in patients with significant liver disease. - Pregnancy safety: avoid use unless clearly needed, as safety data are limited. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several drug classes; interactions are categorized by clinical significance.

Major Interactions (Avoid): - Aliskiren (in diabetes): combined use can increase risk of renal impairment and hyperkalemia. - Dual ARB/ACE inhibitor therapy: may cause excessive hypotension, renal dysfunction, and hyperkalemia. - Potassium‑sparing diuretics: increase risk of dangerous hyperkalemia. - Lithium: can raise lithium levels, leading to toxicity. - NSAIDs (in renal impairment): may worsen kidney function.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance antihypertensive effect, requiring dose adjustment. - CYP3A4 inhibitors (e.g., ketoconazole): can increase irbesartan plasma concentrations. - Other antihypertensives: additive blood‑pressure‑lowering effect may necessitate monitoring.